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1. Introduction
The past few years there have been witnessed the initiation of new or more effective therapies
for the treatment of HIV disease. But it is the established reality for the treatment procedure
of HIV disease; mathematical modeling is very essential and supportive, in accepting the
dynamics of HIV infection and also for the purpose of specific antiviral treatment strategies.
Mathematical models have been constructed to explore the co- relation between disease
progression, generation of HIV specific immune response in primary stage, depletion of CD4+
T cell population, leading to severe impairment and dysregulation of host immune system
and emergence of numerous opportunistic infection. Mathematical model accompanied
with definite biological interpretation and relevance can provide a clear representation of
host-pathogen interaction dynamics. Human Immunodeficiency Virus (HIV) targets the
immune cells mainly CD4 positive T lymphocytes (CD4+T, a type of white blood cells),
which is the main component of immune system. CD4+T cells or " helper" T cells also send
signals to the second group of immune response cells (CD8+T cell or CTL) in the body, the
precursor Cytotoxic T Lymphocytes (CTLp) to induce HIV-specific CTL response through the
generation of functionally active effector CTL (CTLe). HIV infection can be finally eradicated
through co-ordinated interplay between CD4+T cells and CTLs when infected CD4+T cells
are killed by CTLs. Thus, if CTL population can bemaintained at a high level, the HIV-infected
individuals can remain healthy for a longer period of time due to slower disease progression.
The safest and cheapest therapeutic intervention aims to keep the CD4+T cell population
together with CTL count at a positive value, both of which will bring down the viremia to
very low levels.
From an immunological standpoint, progression of HIV can be characterized by continual
reduction of CD4+T lymphocyte subset levels in peripheral compartment and lymphoid
tissue as well, with greater reduction being observed in the former. Dysfunctional
lymphocytes with high propensity for apoptosis and loss of proper cell cycle control account
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for deviation from T cell homeostasis in an HIV-infected individual. HIV antigen activates
immune system, increases cell turnover and induces apoptosis of uninfected CD4+T and
CD8+T cells leading to complete impairment of immune system (Sereti et al., 2004).
Immune activation and subsequent sensitivity to apoptotic stimuli can be reverted back by
introduction of potent antiretroviral agents. Successful therapy with Highly Active Anti
Retroviral Therapy (HAART) efficiently suppresses viral replication but with only partial
immune reconstitution. Moreover, complete eradication of viral population from the system
is practically not feasible with HAART alone, even if continued for a long time. Viral relapse
is known to occur as soon as the therapy is discontinued (Roy & Chatterjee, 2011). Thus
arises the need of addition of new therapeutic modalities in the form of administration of
immunomodulatory agent, IL-2, to the armamentarium of antiretroviral agents promoting
complete immune reconstitution.
IL-2 is a very well characterized T-cell growth factor determining proliferation and
differentiation of whole T cell compartment. Following antigen-activation, IL-2 is produced
by both CD4+ and CD8+T (in comparatively lesser quantities) cell subsets, in the peripheral
lymphoid tissues of spleen and lymph nodes, in an autocrine and paracrine fashion
respectively (Smith, 2001), (Banerjee, 2008).
Infection by HIV affects CD4+T and CD8+T cells in a differential manner with selective
depletion of the CD4+T cells whereas expansion of CD8+T cells is maintained till late stages
of infection (Marchettia et al., 2004). Though IL-2 is produced by CD4+ and CD8+T cells, it
exerts differential effects on CD4+T cells, with preferential expansion and prolonged survival
of peripheral naïve and recall subsets, but not effector and memory phenotype (Sereti et al.,
2004), (Marchettia et al., 2004). IL-2 does not target progenitor cells of the bone marrow
or thymus (Smith, 2001), (De, 2001). Net outcome of IL-2 therapy is rejuvenation of T cell
pool marked by decreases in T cell turnover, proliferation and activation. IL-2 therapy
also increases T cell responsiveness to suboptimal levels of endogenous IL-2 by increasing
expression of its receptor, CD25, on CD4+ T cells (Sklar et al., 2007). CD8+ cells seem to follow
different homeostatic dynamics, more or less independent of immunoregulatory activity of
IL-2. Apart from its regulatory activity on specific cellular populations, IL-2 can also augment
the production of IL-2 itself (Bortolin et al., 2001). In contrast, HAART alone results in selective
rescue of CD4+ memory cells, with no change in naïve compartment (Franzetti et al., 2005).
Thus, IL-2 immunotherapy broadens HAART-induced immune recovery.
The degree of CD4+T cell recuperation after IL-2 administration depends on the nadir CD4+
T cell count and the dose and duration of IL-2 therapy (Paredes et al., 2002). IL-2 can be given
either intravenously or subcutaneously at a low dose intermittently but it is recommended
that it should never be given alone. It should always be administered as an adjuvant to
HAART for maximum biological and clinical benefits. It may be stopped as soon as CD4+T
cell count is "normalized" to pre-infection levels and immune activation is reduced (De, 2001).
Improvement in immunological parameters of the host such as expansion of CD4+T cells may
continue for several months even after IL-2 administration has been interrupted (Bortolin et
al., 2001). The potential of IL-2 to reverse the HIV-mediated T cell homeostasis imbalances by
altering the in vivo dynamics of T-lymphocytes and regulatory cytokines, with transient or
almost no change in HIV viral load, offers the appealing prospect of obtaining major immune
reconstitution in the treatment of HIV disease.
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Several mathematical models have been developed to describe the behavior of the HIV, when
it interacts with the human immune system and causes a decline in the CD4+T cells count
(Bonhoeffer et al., 1997), (Perelson & Nelson, 1999), (Wodarz et al., 2000), (Gumel et al., 2002),
(Roy & Chatterjee, 2010). In their research they expand a innovative thinking, impact of
drag in a HIV individual integrating with their model dynamics. Perelson et al. utilized
clinical data from HIV infected patients and fitted them to their mathematical model and
subsequent numerical simulations to prove the clinical manifestations of AIDS such as long
latency period, depletion of CD4+T cells and low level of free virus in the whole body.
Now a days most of the authors developed their work by including various aspects of HIV
specific antiviral immune response dominated by CTLs because of its significant role in
controlling virus replication and disease progression. A simple mathematical model was
developed by Wodarz et al. (Wodarz et al., 1999) to study the co-relation between HIV and
immune system during the natural course of infection and in the background of different
antiviral treatment regimes. They have suggested the need for an efficient CTL memory
response for effective containment of viral replication. CTL memory is adversely affected
during long-term infection due to depletion of CD4+T cell pool in the system. From analytical
and numerical analysis in their mathematical model, (Roy & Chatterjee, 2011) has been shown
that when the immune response are high, less medication is needed to control and regulate
infection. Their mathematical model also reflect that optimal treatment is reduces the period
of time while the immune response of the uninfected T cell takes over.
Discrete and continuous time delay or time lag is assumed to exist in the various stages of
HIV progression (Herz et al., 1996), (Calshaw et al., 2000), (Roy & Chatterjee, 2011), and (Roy
& Chatterjee, 2010) which have been incorporated into the mathematical model with firm
biological explanations. It is well known that, delay differential equations cause a stable
steady state to lose its stability and cause oscillations. For avoiding the side effects due to
chemotherapy, various mathematical models have been formulated in control therapeutic
approach (Fleming et al., 1975), (Gumel et al., 2002).
In the present paper, the reconstitution dynamics of CD4+T cells and effect on CTLs in
HIV-infected individuals has been studied in presence of HAART and IL-2, where the basic
model as proposed by Wodarz and Nowak has been modified (Wodarz and Nowak). They
have suggested the need for an efficient CTL memory response for effective containment
of viral replication. CTL memory is adversely affected during long-term infection due to
depletion of CD4+T cell pool in the system. Mathematical modeling of such dynamics will
help in delineating the interplay between T lymphocyte subsets in the course of HIV infection
and thereby establishing optimum conditions for effective immune -based therapy associated
with HAART. In this research article delay induced system in the same mathematical model
of HIV has been investigated to understand the effect of combination therapy of HAART and
IL-2. Attempts have also been made to apply the principles of optimal control theory to the
proposed mathematical model for rational administration of IL-2 adjuvanated HAART in an
effort to successfully eradicate the virus from the host system and cure the patient completely.
2. Presentation of the mathematical model
In this research article we develop a viral dynamical model of Wodarz et. al (Wodarz et al.,
1999) by introducing IL-2 therapy in presence of HAART.
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The model is given below,
x˙(t) = λ− β(1− η1u1)x(t)y(t)− dx(t) + γx(t)
y˙(t) = β(1− η1u1)x(t)y(t)− ay(t)− py(t)z(t)
w˙(t) = cx(t)y(t)w(t)− cq1y(t)w(t)− bw(t) + γ1w(t)
z˙(t) = cq2y(t)w(t)− hz(t), (1)
with initial conditions: x(0) > 0, y(0) > 0, w(0) > 0, z(0) > 0.
Here x represents uninfected CD4+T cells, and y, w, z are infected CD4+T cells, Cytotoxic T
lymphocyte precursors (CTLp), CTL effector cells respectively. Here λ represents the rate of
production of CD4+T cells from bone marrow and these immature cells migrate to thymus
and they are matured to immunocompetent T cells. The natural death rate of uninfected
CD4+T cell is d and β is the rate at which uninfected CD4+T cell become infected. Natural
death rate of infected cell is a. The clearance rate of infected cells by CTL effector is p. CTLp
are assumed to proliferate in response to antigenic stimulation and then differentiate into CTL
memory. The rate of proliferation of CTLp population is c and they decay at a rate b. Since
the differentiation rate of precursor CTL (CTLp) not at all same as the proliferation rate of
effector CTL (CTLe), thus we consider q1 and q2 as multiplicative capacity of differentiated
precursor CTL and proliferated effector CTL respectively. We also assume that the removal
rate of effector CTL is h.
Here we introduce IL-2 therapy in presence of HAART. We also consider that the RTI reduces
the infection rate β by (1− η1u1)where η1 represents the drug efficacy parameter and u1 is the
control input doses of the drug RTI. By introducing interleukin protein it enhances the growth
of uninfected T cell and also in a smaller quantity, increases growth of CTLp. Here γ and γ1
are the activation rates of uninfected T cell and CTLp population respectively.
3. General analysis of the mathematical model
Figure 1 shows that, due to introducing of cocktail drug therapy (HAART and IL-2),
uninfected CD4+ T cell moves to its stable position. Further infected CD4+ T cell population
moves to a very lower levels, and ultimately goes towards extinction. Thus effector CTL
population attains a lower steady state, where as CTL precursor enhanced due to effect of
IL-2.
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Fig. 1. Solution trajectory of the non-delayed system. All parameter values are taken from
Table 1.
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3.1 Equilibria and their existence
The system (1) with the initial condition possesses the following positive equilibrium
E1(x1, 0, 0, 0), E2(x2, y2, 0, 0) and E
∗(x∗, y∗,w∗, z∗).
Where, x1 =
λ
d−γ , x2 =
a
β(1−η1u1) , y2 =
β(1−η1u1)λ+a(γ−d)
aβ(1−η1u1) and x
∗ = λ
d+β(1−η1u1)y∗−γ ,
y∗ = −{(d−γ)cq1+β(1−η1u1)(b−γ1)−cλ}+
√
{(d−γ)cq1+β(1−η1u1)(b−γ1)−cλ}2−4acq1β(1−η1u1)(b−γ1)(d−γ)
2cq1β(1−η1u1) ,
w∗ = hβ(1−η1u1)x
∗−ha
cpq2y∗ , z
∗ = β(1−η1u1)x
∗−a
p .
During initial stages of infection when the virus enter in the system but not yet attack any
CD4+T cell, then infection free steady state E1 exists, if d > γ, entail that death rate of
uninfected CD4+T cells is greater than the rate of production of uninfected cells under the
influence of IL-2.
E2 exists if x1 > x2, i.e at early stages of infection when T cells have become infected but CTL
response is yet to develop and it indicates a very crucial situation. It exists when uninfected
cell population at initial stage of infection is greater than steady state value of uninfected T
cell population in presence of infection but without any immune response.
E∗ exists if the following conditions holds, (i) γ−d
β(1−η1u1) < y
∗
< y2, (ii)(b− γ1)(d− γ) < 0.
From the above two conditions we can say that (i) if infected cell population (y∗) at coexistence
equilibrium point lies between these two threshold values and (ii) product of two terms (b−
γ1)(d− γ), i.e. difference between death rate and production rate of CTLp in presence of IL-2
(b − γ1) and difference between death rate and production rate of uninfected CD4+T cell in
presence of IL-2, (d− γ) is negative.
3.2 Stability analysis of the system:
Here we study the nature of stability of the system (1) around different equilibrium points.
From our mathematical study we have the following three propositions.
Proposition 1 : The system (1) is locally asymptotically stable around E1 if the following
condition holds,
(i)γ < d
(ii)γ1 < b
(iii)
β(1−η1u1)λ+a(γ−d)
aβ(1−η1u1) < 0.
Proof :
The s/eigenvalues of the above upper triangular jacobian matrix are
ξ1 = γ− d
ξ2 =
β(1−η1u1)λ
d−γ − a
ξ3 = γ1 − b
ξ4 = −h.
All the characteristic roots corresponding to E1 will be negative if above proposed conditions
are satisfied. Hence the system is locally asymptotically stable around E1. Whenever E1 is
locally asymptotically stable E2 does not exists.
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Proposition 2: System (1) is locally asymptotically stable around E2 if y2 <
β(1−η1u1)(b−γ1)
c(a−q1β(1−η1u1))
holds.
Proof :
By the same way we can prove this proposition.
Proposition 3: The system is locally asymptotically stable around E∗ under R-H criterion for
the following parameter values in Table 1.
Parameters Definition Values assigned
λ Constant rate of production ofCD4+T Cells 10.0 cells/ day
d Death rate of Uninfected CD4+T cells 0.01 cells/ day
β Rate of infection 0.001 cells/ day
a Death rate of infected cells 0.24 cells/ day
p Clearance rate of infected cells by CTLe 0.002 / day
c Rate of proliferation of CTLp 0.6 /day
b Decay rate of CTLp 0.01 /day
h Decay rate of CTLe 0.02/day
γ activation rate of uninfected CD4+T cell by IL-2 0.5/day
γ1 activation rate of CTLp by IL-2 0.1/day
q1 multiplication capacity of differentiated precursor CTL 0.5
q2 multiplication capacity of proliferated effector CTL 0.3
Table 1. Variables and parameters used in the models (1), (2), (16, 17). All parameter values
are taken from (Wodarz et al., 1999), (Calshaw et al., 2000), (Roy & Chatterjee, 2010),
(Bonhoeffer et al., 1997), (Nowak and Bangham, 1996).
4. Delay induced system
In this section we proposed and analyzed the mathematical model (1), incorporating delay
in activation of uninfected CD4+T cell populations through IL-2 therapy. It should be
mentioned here that delay-differential equations demonstrate in a complex dynamics rather
than ordinary-differential equations in view of the fact that a time lag could cause a
stable equilibrium to become unstable and hence the population may be fluctuated. For
better understanding and also for realistic emulation of the delay induced system, we thus
introduced a time delay in the production of CTL in our model (1). We also initiated another
discrete time delay due to the account of the time lag in CTLp activation. Thus we have the
following delay differential equation model in the form of:
x˙(t) = λ− β(1− η1u1)x(t)y(t)− dx(t) + γx(t− τ1)
y˙(t) = β(1− η1u1)x(t)y(t)− ay(t)− py(t)z(t)
w˙(t) = cx(t)y(t)w(t)− cq1y(t)w(t)− bw(t) + γ1w(t− τ2)
z˙(t) = cq2y(t)w(t)− hz(t), (2)
with initial conditions x(θ) = x0 > 0, y(θ) = 0,w(θ) = 0, z(θ) = 0 for θ ∈ [−max{τ1, τ2}, 0].
4.1 Stability analysis of the delay induced system
We further paying our attention to investigate the local asymptomatic stability of the infected
steady state E∗ for the delay induced system (Equation 2). Now linearizing the system (2)
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Fig. 2. Solution trajectory of the delayed system. Here τ1 = 5, τ2 = 0.1, and all other
parameter values are same as Table 1.
about E∗ we get,
dT
dt
= FT(t) + GT(t− τ1) + HT(t− τ2). (3)
Here F,G, H are 4x4 matrices given below,
F =
⎛
⎜⎜⎝
−d− β(1− η1u1)y∗ −β(1− η1u1)x∗ 0 0
β(1− η1u1)y∗ β(1− η1u1)x∗ − a− pz∗ 0 −py∗
cy∗w∗ cx∗w∗ − cq1w∗ cx∗y∗ − cq1y∗ − b 0
0 cq2w
∗ cq2y∗ −h
⎞
⎟⎟⎠
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Fig. 3. Solution trajectory of the delayed system. Here τ1 = 1, τ2 = 0, and all other parameter
values are same as Table 1.
G =
⎛
⎜⎜⎝
γ 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
⎞
⎟⎟⎠
H =
⎛
⎜⎜⎝
0 0 0 0
0 0 0 0
0 0 γ1 0
0 0 0 0
⎞
⎟⎟⎠
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The characteristic equation of system (2) is given by,
△(ξ) =| ξ I − F− e−ξτ1G− e−ξτ2 H |= 0.
This equation can be written as,
ψ(ξ, τ1, τ2) = ξ
4 + A1ξ
3 + A2ξ
2 + A3ξ + A4ξ + e
−ξτ1 [B1ξ3 + B2ξ2 + B3ξ + B4]
e−ξτ2 [C1ξ3 + C2ξ2 + C3ξ + C4] + e−ξ(τ1+τ2)[D1ξ2 + D2ξ + D3] = 0. (4)
The coefficients are given below,
m11 = −d− β(1− η1u1)y∗, m12 = −β(1− η1u1)x∗, m21 = β(1− η1u1)y∗,
m22 = β(1− η1u1)x∗ − a− pz∗ , m24 = py∗ , m31 = cy∗w∗, m32 = cx∗w∗ − cq1w∗,
m33 = cx
∗y∗ − cq1y∗ − b, m42 = cq2w∗,m43 = cq2y∗,m44 = −h,
where,
A1 = m44 −m33 −m22 −m11,
A2 = m33m44 + m11m44 + m22m44 + m22m33 + m11m33 + m22m11 −m12m21 −m24m42,
A3 = −m11m33m44 −m22m33m44 −m11m22m44 + m12m21m44 −m24m32m43,
+ m24m33m42 + m11m24m42 + m11m24m42 −m11m22m33 + m12m21m33,
A4 = m11m22m33m44 −m12m21m33m44 + m11m24m32m43 −m12m24m31m43
− m11m24m33m42,
B1 = −γ,
B2 = γ(m44 + m33m22),
B3 = γ(−m33m44 −m22m44 −m22m33 + m24m42),
B4 = γ(m22m33m44 + m24m32m43 −m24m33m42),
C1 = −γ1,
C2 = γ1(m44 + m22m11),
C3 = γ1(−m22m44 −m11m44 −m22m11 + m24m42),
C4 = γ1(m11m22m44 −m12m21m44 −m11m24m42),
D1 = γγ1,
D2 = γγ1(−m22m44),
D3 = γγ1(m22m44).
The characteristic equation (4) is a transcendental equation in ξ. It is known that E∗ is
locally asymptotically stable if all the roots of the corresponding characteristic equation have
negative real parts and unstable if purely imaginary roots are appears. As we know that
the transcendental equation has infinitely many complex roots (Calshaw et al., 2000), so in
presence of τ1, τ2, analysis of the sign of roots is very complicated. Thus, we begin our analysis
by setting one delay which is equal to zero and then deduce the conditions for stability, when
both time delays are non zero.
6 Insight and Control of Infectious Disease in Glo al Scenario
www.intechopen.com
Mathematical Modeling of IL-2 Based Immune Therapy on T Cell Homeostasis in HIV 9
Case I :- When τ1 = τ2 = 0 :
In absence of both the delays the characteristics equation (4) becomes,
ξ4 + ξ3(A1 + B1 + C1) + ξ
2(A2 + B2 + C2 + D1) + ξ(A3 + B3 + C3 + D2)
+(A4 + B4 + C4 + D3) = 0. (5)
Employing Routh Hurwitz criteria for sign of roots we have the same results as in non delayed
system analysis.
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Fig. 4. Solution trajectory of the delayed system. Here τ1 = 0.2, τ2 = 5, and all other
parameter values are same as Table 1.
Case II :- When τ1 > 0, τ2 = 0 :
In this case we consider no delay in CTL precursor immune response i.e τ2 = 0, then the
characteristic equation becomes,
ξ4 + ξ3(A1 + C1) + ξ
2(A2 + C2) + ξ(A3 + C3) + (A4 + C4)
+e−ξτ1 [B1ξ3 + ξ2(B2 + D1) + ξ(B3 + D2) + (B4 + D3)] = 0. (6)
For τ1 > 0, (6) has infinitely many roots. Using Rouche’s theorem and continuity of τ1, the
transcedental equation has roots with positive real parts if and only if it has purely imaginary
roots. Let iθ be a root of equation (6) and hence we get,
θ4 − θ2(A2 + C2) + (A4 + C4) = cos θτ1[θ2(B2 + D1)− (B4 + D3)]
+ sin θτ1[θ
3D1 − θ(B3 + D2)]
θ(A3 + C3)− θ3(A1 + C1) = cos θτ1[θ3D1 − θ(B3 + D2)]
− sin θτ1[θ2(B2 + D1)− (B4 + D3)]. (7)
Squaring and adding above two equations,
θ8 + θ6[(A1 + C1)
2 − 2(A2 + C2)− D21 ]
+θ4[(A2 + C2)
2 + 2(A4 + C4)− 2(A3 + C3)(A1 + C1)− (B2 + D1)2
+2D1(B3 + D2)] + θ
2[(A3 + C3)
2
−2(A2 + C2)(A4 + C4) + 2(B2 + D1)(B4 + D3)− (B3 + D2)2]
+[(A4 + C4)
2 − (B4 + D3)2] = 0. (8)
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Fig. 5. Solution trajectory of the delayed system. Here τ1 = 0, τ2 = 1, and all other parameter
values are same as Table 1.
Simplifying and substituting θ2 = l in equation (8) we get the following equation,
l4 + α1l
3 + α2l
2 + α3l + α4 = 0. (9)
Where,
α1 = (A1 + C1)
2 − 2(A2 + C2)− D21 ,
α2 = (A2 + C2)
2 + 2(A4 + C4)− 2(A3 + C3)(A1 + C1)− (B2 + D1)2 + 2D1(B3 + D2),
α3 = (A3 + C3)
2 − 2(A2 + C2)(A4 + C4) + 2(B2 + D1)(B4 + D3)− (B3 + D2)2,
α4 = (A4 + C4)
2 − (B4 + D3)2.
It may be noted that the equation (9) will have negative real part if and only if Routh-Hurwitz
criterion is satisfied and hence equation (6) will have no purely imaginary root. From the
above analysis we have the following proposition.
Proposition 4 : In the delay induced system (2), the infected steady state E∗ will be locally
asymptotically stable for all τ1 > 0 if the following conditions are satisfied:
α1 > 0, α4 > 0, ψ = α1α2 − α3 > 0, ψα3 − α21α4 > 0.
Case III :- When τ1 = 0, τ2 > 0 :
In absence of τ1, the characteristic equation (4) have the following form,
ξ4 + ξ3(A1 + B1) + ξ
2(A2 + B2) + ξ(A3 + B3) + (A4 + B4)
+e−ξτ2 [C1ξ3 + ξ2(C2 + D1) + ξ(C3 + D2) + (C4 + D3)] = 0.
(10)
Similarly as in case II we substitute ξ = iθ and we get,
θ4 − θ2(A2 + B2) + (A4 + B4) = cos θτ2[θ2(C2 + D1)− (C4 + D3)]
+ sin θτ2[θ
3C1 − θ(C3 + D2)]. (11)
θ(A3 + B3)− θ3(A1 + B1) = cos θτ2[θ3C1 − θ(C3 + D2)]
− sin θτ1[θ2(C2 + D1)− (C4 + D3)]. (12)
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Squaring and adding, and then substituting θ2 = s we have,
s4 + δ1s
3 + δ2s
2 + δ3s + δ4 = 0. (13)
Where,
δ1 = (A1 + B1)
2 − 2(A2 + B2)− C21
δ2 = (A2 + B2)
2 + 2(A4 + B4)− 2(A3 + B3)(A1 + B1)− (C2 + D1)2 + 2C1(C3 + D2)
δ3 = (A3 + B3)
2 − 2(A2 + B2)(A4 + B4) + 2(C2 + D1)(C4 + D3)− (C3 + D2)2
δ4 = (A4 + B4)
2 − (C4 + D3)2.
From the above analysis we have the following proposition.
Proposition 5 : In the delay induced system (2), the infected steady state E∗ will be locally
asymptotically stable for all τ2 > 0 if the following conditions are satisfied
δ1 > 0, δ4 > 0, ϕ = δ1δ2 − δ3 > 0, ϕδ3 − δ21δ4 > 0. If δ4 < 0 then we have the following
proposition,
Proposition 6 : Equation (13) admits at least one positive root if δ4 < 0 is satisfied.
If θ0 be a positive root of (13), then equation (10) will have a purely imaginary root ±iθ0
corresponding to τ2. Now we evaluate the critical value of τ2 for which the deley induced
system (2) remain stable. From equation (11,12),
τ∗2 =
acosφ(θ0)
θ0
. (14)
Where,
φ(θ0) = [{θ2(C2 + D1)− (C4 + D3)}{θ4 − θ2(A2 + B2) + (A4 + B4)}
+{θ3C1 − θ(C3 + D2)}{θ(A3 + B3)− θ3(A1 + B1)}]
÷[{θ2(C2 + D1)− (C4 + D3)}2 + {θ3C1 − θ(C3 + D2)}2]. (15)
From the above analysis we construct the following theorem.
Theorem 1 :
If δ4 < 0 is satisfied, then the steady state E
∗ is locally asymptotically stable for τ2 < τ∗2 and
becomes unstable for τ2 > τ
∗
2 . When τ2 = τ
∗
2 a Hopf bifurcation occurs.
Case IV :- τ1 > 0, τ2 > 0
In this case we studied the stability of the steady state E∗ in presence of both delays. If all
the roots of equation (10) have negative real parts for τ > 0 i.e when the system is locally
asymptotically stable then there exists a τ∗1 depending upon τ2 such that all roots of equation
(4) have negative real parts whenever τ1 < τ
∗
1 . Considering all the cases we have the following
theorem .
Theorem 2 : Whenever δ4 < 0 holds then for τ2 < τ
∗
2 , there exists a τ
∗
1 depending upon τ2 the
steady state E∗ is locally asymptotically stable for τ1 < τ∗1 and τ2 < τ
∗
2 .
Special Remarks of the Delay Induced System in view of Numerical Analysis:
Though it is eventually true from our analytical results that for a longer value of delay the
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Fig. 6. This figure shows the system behavior for the Optimal treatment schedule of the
control variable u1(t) and u2(t) for R = 0.1, P = 0.5, and η1 = 0.5, η2 = 0.1, η3 = 0.01. All
other parameter values are same as Table 1.
system become unstable (Theorem 1 and Theorem 2), however it is essential to mention here
that in our delay induced system, numerical analysis reveal, when τ1 = 0 and τ2 = 1, its
reflect from solution trajectory, there are no such oscillations in Figure, which may conclude
that delay does affect the stability of the system.
Further we change the values of both delays τ1, and τ2, and varied them from 1 to 20, we
also observe that no significant changes does arise in each case for which we can express that
delay affect the stability of the system. Thus, in a nutshell we can say that incorporation of
time delay into the existing model to account for time lag in activation of CTLp did not exhibit
any biologically significant interpretation.
5. The optimal control problem
In this section our main object is to minimize the infected CD4+T cells population as well as
minimize the systemic cost of drug treatment. Here we formulate an optimal control problem.
We also want to maximize the level of healthy CD4+T cells. So in our basic model (1), we use
control variables u1(t), u2(t) represents the drug dose satisfying 0 ≤ u1(t) ≤ 1 and 0 ≤
u2(t) ≤ 1. Here u1(t) = 1, u2(t) = 1 events are represents the maximal use of chemotherapy
and u1(t) = 0, u2(t) = 0 represents no treatment.
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Here we consider that the RTI reduces the infection rate by (1− η1u1), where η1 represents
the drug efficacy and u1 is the control input doses of the drug RTI. We also consider the
enrichment of uninfected T cell and CTL responses through IL-2 treatment is given by η2u2,
and η3u2, where u2 as a control input of IL-2 treatment and η2, η3 are the drug efficacy of IL-2
for uninfected T cell and precursor CTL responses.
In this section our main aim is to minimize the cost as well as minimize the infected CD4+T
cell and maximize the uninfected CD4+T cell. Thus we construct the optimal control problem
where the state system is
x˙ = λ− dx − β(1− η1u1(t))xy + (1− η2u2(t))γx
y˙ = β(1− η1u1(t))xy− ay− pyz
w˙ = cxyw− cq1yw− bw + (1− η3u2(t))γ1w
z˙ = cq2yw− hz, (16)
and the control function is defined as
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Fig. 7. This figure shows the system behavior for the Optimal treatment schedule of the
control variable u1(t) and u2(t) for R = 10, P = 50, and η1 = 0.1, η2 = 0.1, η3 = 0.01. All
other parameter values are same as Table 1.
J(u1, u2) =
∫ t f
t0
[y(t)− x(t)− w(t) + Ru21 + Pu22]dt. (17)
Where the parameter R and P respectively the weight on the benefit of the cost.
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Here the control function u1(t) and u2(t) are bounded, Lebesgue integrable function (Swan,
1984).
In this problem we are seeking the optimal control pair (u1
∗, u2∗) such that
J(u1
∗, u2∗) = min{J(u1, u2) : (u1, u2) ∈ U}.
Here U is the control set defined by
U = {u = (u1, u2) : u1, u2 are the measurable, 0 ≤ u1(t) ≤ 1, 0 ≤ u2(t) ≤ 1, t ∈ [t0, t f ]}.
To determine the optimal control u1
∗ and u2∗, we use the “Pontryagin Minimum Principle”
(Pontryagin et al., 1986). To solve the problem we use the Hamiltonian given by
H = y(t)− x(t)− w(t) + Ru21 + Pu22 + ξ1{λ− dx − β(1− η1u1(t))xy + (1− η2u2(t))γx}
+ξ2{β(1− η1u1(t))xy− ay− pyz}+ ξ3{cxyw− cq1yw− bw + (1− η3u2(t))γ1w}
+ξ4{cq2yw− hz}. (18)
By using the “Pontryagin Minimum Principle” and the existence condition for the optimal
control theory (Fleming et al., 1975) we obtain the theorem.
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Fig. 8. This figure shows the system behavior for the Optimal treatment schedule of the
control variable u1(t) and u2(t) for R = 10, P = 50, and η1 = 0.6, η2 = 0.1, η3 = 0.01. All
other parameter values are same as Table 1.
Theorem: The objective cost function J(u1, u2) over U is minimum for the optimal control
u∗ = (u1∗, u2∗) corresponding to the interior equilibrium (x∗, y∗,w∗, z∗). Also there exist
adjoint function ξ1, ξ2, ξ3, ξ4 satisfying the equation (18) and (19).
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Proof: By using Pontryagin Minimum principle (Fleming et al., 1975) the unconstrained
optimal control variable u1
∗ and u2∗ satisfy
∂H
∂u1∗
=
∂H
∂u2∗
= 0. (19)
Since
H = [Ru21 − ξ1(1− η1u1(t))βxy + ξ2(1− η1u1(t))βxy] + [Pu22 + ξ1(1− η2u2)γx
+ξ3(1− η3u2)γ1w] + other terms without u1 and u2, (20)
then we obtain ∂H∂ui∗
for ui
∗ where (i = 1, 2), and hence equation with zero becomes,
∂H
∂u1∗
= 2Ru1
∗ + η1βx∗y∗(ξ1 − ξ2) = 0
∂H
∂u2∗
= 2Pu2
∗ − ξ1η2γx∗ − ξ3η3γ1z∗ = 0.
Thus we obtain the optimal control u1
∗ and u2∗ corresponding to the interior equilibrium
(x∗ , y∗,w∗, z∗) as,
u1
∗ = βη1x
∗y∗(ξ2 − ξ1)
2R
u2
∗ = (ξ1η2γx
∗ + ξ3η3γ1z∗)
2P
. (21)
According to Pontryagin minimum Principle (Pontryagin et al., 1986) we know that,
dξ
dt
= − ∂H
∂x
, (22)
and
H(x(t), u∗(t), ξ(t), t) = min
u∈U
H(x(t), u(t), ξ(t), t). (23)
The above equations are the necessary conditions satisfying the optimal control u(t) and
again for the system (16, 17) the adjoint equations are
dξ1
dt = − ∂H∂x , dξ2dt = − ∂H∂y , dξ3dt = − ∂H∂w , dξ4dt = − ∂H∂z .
Taking the partial derivative of H we get,
dξ1
dt
= 1+ ξ1{d1 + (1− η1u1(t))βy− (1− η2u2(t))γ} − ξ2(1− η1u1(t))βy− ξ3cyw
dξ2
dt
= −1+ ξ1(1− η1u1(t))βx − ξ2{(1− η1u1(t))βx − a− pz} − ξ3{cxw− cq1w} − ξ4cq2w
dξ3
dt
= 1− ξ3{cxy− cq1y− b + (1− η3u2(t))γ1} − ξ4cq2y
dξ4
dt
= ξ2py + ξ4h. (24)
Hence the optimality of the system consists of the state system along with the adjoint system.
Also it depends on the initial conditions and the transversality condition which satisfy
ξi(t f ) = 0 and x(0) = x0, y(0) = y0, w(0) = w0, z(0) = z0.
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Fig. 9. This figure shows the system behavior for the Optimal treatment schedule of the
control variable u1(t) and u2(t) for R = 10, P = 50, and η1 = 0.8, η2 = 0.4, η3 = 0.1. All
other parameter values are same as Table 1.
6. Conclusion
In this research article we have considered a mathematical model of immune system
representing the response of a HIV infected individual in presence of HAART and IL-2. We
have studied how the immune system recovers by applying IL-2 as an immune activator
along with HAART. We have also observed the effect of delay in activation of uninfected
CD4+T populations through IL-2 therapy. We have noticed the control therapy, which is
more effective with respect to cost and also less side effect. Here analytical as well as
numerical approaches have been observed. We have also noticed that, the rational behind
concomitant administration of IL-2 with HAART is to augment host immune responses
through prevention of destruction of the immunity system without stimulation of HIV
replication. In the beginning of our research article, our mathematical model of HIV dynamics
in presence of HAART and IL-2 suggest the existence of three equilibrium conditions :
E1(x1, 0, 0, 0), E2(x2, y2, 0, 0) and E
∗(x∗, y∗,w∗, z∗). Our analytical studies first indicates the
infection free steady state or uninfected equilibrium, where CD4+T cells are healthy and no
infected cell population exists and there is no HIV-specific CTL immune response. The second
equilibrium condition is not a very desirable one since there is no immune response even in
presence of HIV antigen. The third equilibrium state or infected steady state is said to be
exist at certain limiting values of infected cell population in presence of HAART and IL-2.
We also studied the stability of the system for different equilibrium points. Further a time
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delay has been introduced into the existing model to account for the activation of immune
response through infected CD4+T cells. In that study, we noticed that delay induced system
has no useful delay effect which changes its stability. From optimal control studies, several
interesting results have been obtained. As weight factors ( R and P) increase from 0.1 to 10
and 0.5 to 50 respectively, there is a significant increase in the uninfected cell population with
very little effect on the count of infected cells. The increase in the weight factors does not
produce proportionate increase in the precursor CTL population and increase in effectiveness
of HAART or IL-2 as denoted by η, is not manifested by remarkable change in precursor CTL
number. The CTL effector population is found to decrease in all the cases. Thus, optimal
control approach will help in designing an innovative cost-effective safe therapeutic regimen
of HAART and IL-2 where the uninfected cell population will be enhanced with simultaneous
decrease in the infected cell population. Moreover, successful immune reconstitution can
also be achieved with increase in precursor CTL population. Mathematical modeling of
viral dynamics thus enables maximization of therapeutic outcome even in case of multiple
therapies with specific goal of reversal of immunity impairment.
From our above discussion of the results, it is clear that, though incorporation of time delay
into the existing model (1) to account for time lag in activation of CTLp did not exhibit
any biologically significant interpretation, however, adoption of optimal control strategy in
optimization of therapeutic regime of combination therapy of HAART and IL-2 was found
to be really satisfactory in terms of enhancing the life expectancy of HIV-afflicted patients by
improving the uninfected T cell count.
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